|


Foundation for Decision Making, Liver Wellness and
Prevention of Hepatitis and Drug Abuse
Learn new techniques to protect yourself, your
staff and your patients. We can train your staff, healthcare
providers, and educators.
Call 1-800-891-0707 for information.

Join our
cause!
NNAC
National Nurses Advisory Council
Join Nurses (NNAC)
Around the Nation to fill gaps in patient care and prevention initiatives!
CFC / United Way
Way
2009
Your United Way donation can be
made directly to HFI and UW will still get credit. Give a check made
out to HFI to your captain to get credit for UW and avoid paying
administrative costs.
Win Win for HFI, CFC, UW, and You
Federal Employees Can Choose

Hepatitis Foundation International
Make HFI -
Your Charity Of Choice
Our CFC Agency Code:
11842
|
Southeastern
Viral Hepatitis Summit
Durham,
North Carolina
Hepatitis
Foundation International announces a 1 day
professional education and training Summit for health
professionals
and others working with people who are affected by or
infected with viral hepatitis, including:

 
Registration
information will follow soon
Good News!
The Hepatitis B and Hepatitis C bills
have been combined in a
bipartisan bill –
Viral Hepatitis and Liver Cancer Control and
Prevention Act 2009 (HR 3974) and introduced in Congress by
U.S. Representative Mike Honda (D-CA) and Charles Dent (R-PA)
on October 29. This bill will expand education for patients
and
health care providers, increase access to hepatitis testing
and
live cancer screening, improve the capacity of health
departments
and support viral hepatitis prevention and education program
across the nation.
Click here to read the
bill.
Breaking
News
View "Give Your Liver A Break", an Emmy Awarded DVD on
YouTube.
Click here
Targeted Therapy Extends Survival for Liver Cancer
Primary liver cell cancer is increasing in the U.S.
Recent data
suggest that the incidence rate has risen to
approximately 5
per 100,000 but the five-year survival remains
suboptimal with
8% overall survival in the United States. Thus there is
a clear
unmet need for more effective therapies.
Click here.
Hepatitis C virus (HCV) progresses more rapidly after
liver transplantation in African-Americans
Previous studies have shown
that hepatitis C virus (HCV)
progresses slower prior to liver transplantation in
African
Americans than in whites.
Click here.
Twice
Daily Oral Medication Shows Promise in Hepatitis C
Researchers treated patients -
both treatment naive and
experienced patients - with a twice daily oral
combination
therapy of a nucleoside polymerase and protease
inhibitor.
The results were significant antiviral potency
and sustained
viral reductions.
Click here.
Viral Load Predicts Outcome of Liver Transplant
Recipients
with
HCV
Viral load is an important
factor and can predict the outcome
of patients with hepatitis C virus (HCV) after liver
transplantation, for both the development of the
different
types of recurrent HCV and patient survival.
Click here.
Survival
Lower in HCV-Infected Women after Liver Transplant
Women undergoing liver
transplant as a result of hepatitis C
virus (HCV) infection show poorer long-term survival
rates and
more frequent failure of the donor liver, compared with
male
recipients.
Click here.
New Biomarker Predicts Response to Hepatitis C Treatment
Researchers at Duke University
Medical Center have identified
the first genetic marker that predicts response to hepatitis C
treatments, and a single letter of DNA code appears to make a
huge difference. Scientists say the biomarker not only predicts
who is most likely to respond to treatment and who isn’t, but
also may explain why there are such different response rates
among racial and ethnic groups. Click here.

Articles of Interest
Impact of Lifestyles on
Hepatitis C
In HCV-infected
patients, the top three predictors of liver
related mortality were having higher body mass index (BMI),
presence of insulin resistance (IR), and elevated serum
cholesterol. Overall mortality in HCV patients was most linked
to metabolic syndrome, higher BMI and hypertension.
Click here for more information.
Telaprevir Effective in Treating Previously Failured Response
Vertex’s telaprevir,
an experimental drug for hepatitis C, is
showing that it can cure about half of the patients
who failed
to respond to standard treatments. The study found
that 51
percent of patients who took telaprevir in
combination with
standard drugs for six months were cured and 52
percent were
cured.
Click here for more information.
Phase 3
Albureron Trials Show Promising Results
The Phase 3 studies conducted by
Human Genome Sciences,
Inc, known as ACHIEVE 1 and ACHIEVE 2/3, evaluated
albinterferon alfa-2b vs. ginterferon alfa-2a, in combination
with ribavirin, for use in the treatment of interferon-naive
patients with chronic hepatitis C.
Click here for more information.
Acetaminophen Painkillers to
Carry Stronger Risk Warnings
Pain relieving drugs containing Acetaminophen will be
required
to carry more explicit warning labels about the
risk of liver damage
and stomach bleeding especially for
people who
overdose on pain medicines or who drink three
or more
alcoholic drinks each day.
Click here for more information.
|
Your online purchases can benefit HFI at no cost to you!
Get updates on research advances and HFI's work in promoting liver
wellness
Join Our
Email List

***
HFI CEO Alerts Millions About Hepatitis

Click here to
watch.
Donate to HFI
Hepatitis Foundation
International (HFI) continues to work hard to provide up to date
information and motivational messages for patients, educators, and
the healthcare community. We need your help to continue this
important work!
Your donation to HFI can make a significant difference!
Hepatitis Foundation International
504 Blick Drive Silver Spring, MD 20904-2901 USA
tel:
301-622-4200 800-891-0707 fax: 301-622-4702 |